Antibody-drug conjugates (ADCs) are promising biotherapeutics composed of an antibody plus a cytotoxic payload via a chemical linker, thus allowing the delivery of cytotoxic payload to target cancer cells. Among cancer glycoproteins studied in cancer research, mucin-1 (MUC1) is among the most extensively researched.